Pfizer restructures executive team as reputation chief departs - Bloomberg

Published 08/07/2025, 16:40
© Reuters

Investing.com -- Pfizer Inc. (NYSE:PFE) is undergoing a corporate restructuring that includes the departure of Sally Susman, the company’s chief corporate affairs officer who has managed public communications for nearly two decades, Bloomberg reports.

According to Bloomberg, citing an email sent by Chief Executive Officer Albert Bourla on Tuesday, Susman’s responsibilities will be divided among five executives at the company. The email described the move as a mutual decision. Four of Susman’s top deputies will also leave the company.

The executives who will take over Susman’s duties will evaluate each division "for potential simplification and cost reduction," Bourla wrote in the companywide message.

This restructuring comes as Pfizer works to cut more than $7 billion from its spending through 2027. The cost-cutting initiative aims to strengthen the company’s balance sheet following a significant decline in demand for its Covid-19 vaccine and treatment since the pandemic’s peak.

Susman, who joined Pfizer in 2007, has effectively served as the company’s chief reputation officer, leading communications, government relations, and patient advocacy efforts across five presidential administrations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.